research Antiandrogens for the Treatment of Hirsutism: A Systematic Review and Metaanalyses of Randomized Controlled Trials
Antiandrogens are somewhat effective in reducing excessive hair growth in women.
Search
for
Sort by
Research
150-180 / 1000+ results 
research Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women
GnRH analogue can help diagnose ovarian causes of high testosterone in postmenopausal women when scans don't show the cause.
research Interventions for Hirsutism
Oral contraceptives help mild hirsutism, while flutamide and spironolactone help severe cases.
research Dienogest versus gonadotropin-releasing hormone analogues for the clinical treatment of endometriosis: an updated meta-analysis
Dienogest is safer and has fewer side effects than GnRH analogues for treating endometriosis.
research A Hero Revealed: Targeting the AHR for treatment of inflammatory skin diseases
AHR ligands could treat inflammatory skin diseases.
research Application of histamine receptors H2R, H3R and H4R, but not H1R, in dermatology
Certain histamine receptors (H2R, H3R, H4R) have unique roles in treating skin diseases, with H2R helping with chronic urticaria and other conditions, H3R providing pain relief and allergy benefits, and H4R reducing inflammation and itchiness.
research Topical Finasteride Therapy in Hirsutism
Topical finasteride may help treat facial hirsutism in women.
research Insights learned from L457(3.43)R, an activating mutant of the human lutropin receptor
The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
research Parathyroid hormone-related peptide and the hair cycle - is it the agonists or the antagonists that cause hair growth?
PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.
research Regulation of the metabolic phenotype of human hepatocytes by glucocorticoids and androgens
Glucocorticoids reduce fat production in liver cells, while androgens increase it in females; manipulating certain enzymes can influence these effects.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
GLP-1RA therapy may increase the risk of hair loss.
research SUN-106 Nonsurgical Management of Hyperandrogenism in a Postmenopausal Woman
Goserelin injections can effectively manage hyperandrogenism symptoms in postmenopausal women who can't have surgery.
research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
research Gender-Affirming Hormone Therapy Among Transgender and Gender Diverse Patients Receiving Laser Hair Removal Prior to Gender-Affirming Surgery
Most transgender patients getting laser hair removal before gender-affirming surgery are already on hormone therapy, which might affect the hair removal process.
research Hormonal Treatment for Skin Androgen-Related Disorders
Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.
research Spironolactone Therapy for Hirsutism in a Hyperandrogenic Woman
Spironolactone may help reduce excessive hair growth in women with high male hormone levels.
research CHRONIC TREATMENT REGIMENS FOR HIRSUTISM IN WOMEN: EFFECT ON BLOOD PRODUCTION RATES OF TESTOSTERONE AND ON HAIR GROWTH
Combination therapy significantly reduces testosterone and moderately reduces hair growth in women with hirsutism.
research ANTI‐ANDROGENS IN HIRSUTISM
Cyproterone acetate effectively treats hirsutism and related conditions.
research Lymphomatoid papulosis improving on hormone-replacement therapy
Hormone-replacement therapy improved a woman's skin condition known as lymphomatoid papulosis.
research Corticotropin-releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes
CRH promotes fat production in skin cells, affecting conditions like acne.
research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
GLP-1 agonists may increase the risk of hair loss.
research Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism
All three treatments reduce hirsutism, but spironolactone works best long-term.
research Thyrotropin releasing hormone (TRH): a new player in human hair‐growth control
TRH stimulates human hair growth and extends the hair growth phase.
research Targeting Pharmacological and Nanotechnology Based Therapeutics for Management of Hirsutism: A Comprehensive State-of-the-Art
New treatments for excessive hair growth in women, including advanced drugs and nanotechnology, show promise for better results.
research [Hirsutism and hypertrichosis in adults: investigations and treatment].
The document concludes that treatment for excessive hair growth depends on the cause, with options including hair removal methods and medications like anti-androgens or insulin-sensitizing drugs.
research Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne
Spironolactone may reduce excessive hair growth in women but its effectiveness for acne is not supported.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.